This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary BTK Therapeutic Antibody Development
Therapeutic antibodies have provided new treatment options for many diseases in companion animals. Choosing the right, potent target is the cornerstone of developing veterinary therapeutic antibodies. BioVenic offers services in developing antibodies targeting BTK, utilizing its comprehensive platform for veterinary therapeutic antibody development. This service is aimed at assisting in developing therapeutic antibodies against the BTK-encoded protein, advancing the treatment of canine and feline cancers and autoimmune diseases.
Background of BTK
| Full Name | Bruton tyrosine kinase |
|---|---|
| Aliases | AT, ATK, AGMX1, BPK, IMD1, IGHD3, PSCTK1, XLA. |
| Target Profile | As a member of the TEC family of non-receptor cytoplasmic tyrosine kinases, the protein encoded by the BTK gene is a key kinase in the BCR (B-cell antigen receptor) signaling pathway, playing a significant role in the growth, development, and proliferative differentiation of B cells. BTK is exclusively expressed in differentiating B cells and is not present in T cells or normal plasma cells. |
MoA of BTK
BTK can be activated by the upstream molecule spleen tyrosine kinase (SYK) and in turn activates the downstream phospholipase Cγ2 (PLCG2), ultimately promoting the nuclear translocation of nuclear factor κB (NF-κB) thereby inducing B cell proliferation. The overexpression of BTK can lead to abnormal activation of the BCR signaling pathway, activating a variety of downstream signaling molecules. This excessive activation of downstream molecules continuously enhances cell survival signals and inhibits apoptosis, resulting in the development of B-cell malignancies. It can also cause dysfunction of B cells and alteration in the state of immune tolerance, transforming them into auto-reactive B cells that secrete large quantities of autoantibodies, thus inducing autoimmune diseases.
Fig.1 Schematic diagram of BTK in BCR signaling, TCR signaling, and chemokine receptor signaling pathway.1,2
Application in Veterinary Therapeutics
In companion animals, such as canines and felines, the abnormal activation of BTK is associated with various diseases, particularly cancers, and autoimmune disorders, including canine B-cell lymphoma and canine pemphigus foliaceus, as well as feline mast cell tumors. By inhibiting the activity of BTK, the proliferation and survival signals of tumor B cells can be blocked, thereby inhibiting tumor growth. It can also reduce the number and activity of these auto-reactive B cells, helping to control symptoms of autoimmune diseases. The use of BTK therapeutic antibodies is a targeted treatment approach, focusing on specific molecular pathways to enhance the precision of disease treatment in canine and feline. This method minimizes the impact on normal cells within the animal's body, offering a more precise and less harmful treatment option.
Veterinary BTK Therapeutic Antibody Development Services
Considering the significant role of BTK in canine and feline diseases, particularly B-cell lymphoma and certain autoimmune disorders, BioVenic offers services for veterinary BTK therapeutic antibody development. Utilizing various advanced technologies, we assist in developing veterinary therapeutic antibodies specifically aimed at modulating BTK activity, thereby providing safer and more effective treatment options for companion animals like canines and felines. Our services extend beyond mere development and include comprehensive antibody characterization, engineering, and species-specific antibody development, ensuring that the veterinary BTK therapeutic antibodies effectively achieve the desired therapeutic outcomes.
For more information on how we develop veterinary BTK therapeutic antibodies, please click the link below.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
A wide range of technology platforms for veterinary therapeutic antibody development is available for you to choose from, including hybridoma cell technology, single B-cell technology, and phage display technology.
Full-service supply covering the entire process, including preparation, characterization, engineering, and other steps of veterinary therapeutic antibody development.
We provide species-specific therapeutic antibody development services to reduce the immunogenicity of BTK therapeutic antibodies in companion animals, such as dogs and cats, and to improve antibody safety and efficacy.
The BTK gene is a key player in several animal diseases, particularly in those involving B-cell malignancies and autoimmune disorders, such as canine lymphoma. BioVenic provides veterinary BTK therapeutic antibody development services, from preparation to optimization and development of species-specific antibodies. If you are exploring the possibility of developing veterinary BTK therapeutic antibodies for the treatment of conditions like B-cell tumors in canine and feline, we invite you to reach out to us, to ensure tailored solutions for your specific needs.
Reference
- Wen, Tingyu, et al., "Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances." Leukemia 35.2 (2021): 312-332.
- Image retrieved from Figure 3 "A schematic map of BTK in BCR signalling, TCR signalling, and chemokine receptor signalling pathway.", Wen, Tingyu, et al., 2021, used under [CC BY 4.0], the image title was changed to "Schematic diagram of BTK in BCR signaling, TCR signaling, and chemokine receptor signaling pathway."